TITLE

Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women

AUTHOR(S)
Mattsson, L. A.; Skouby, S.; Rees, M.; Heikkinen, J.; Kudela, M.; Stadnicki-Kolendo, A.; Mattila, L.; Salminen, K.; Vuorela, A.; Mustonen, M.
PUB. DATE
September 2007
SOURCE
Menopause International;Sep2007, Vol. 13 Issue 3, p124
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective. Continuous combined hormone replacement therapy (ccHRT) based on estradiol valerate (E2V) and medroxyprogesterone acetate (MPA) is effective for relief of menopausal symptoms three years or more after the menopause. This study was undertaken to examine the efficacy and tolerability of ccHRT in early postmenopausal women (last menstrual period 1-3 years before study entry). Study design. This was a 52-week, randomized, double-blind, multinational study of ccHRT comprising three different dose combinations of E2V/MPA in 459 early postmenopausal non-hysterectomized women experiencing 30 or more moderate to severe hot flushes a week and/or vasomotor symptoms requiring treatment. Main outcomes measures. The primary endpoint was change in frequency and severity of moderate to severe hot flushes at 12 weeks. Secondary outcome measures included number of bleeding days and evaluation of tolerability. Results. The frequency of hot flushes was reduced by ≥ 70% after one month (P < 0.001 for all doses at week 2 onwards), with little evidence of statistically different dose effects. Severity of flushing was also attenuated by ccHRT. Mean number of bleeding days fell to < 1 per 28-day cycle at 52 weeks. Rates of amenorrhoea approached 80-90% at the end of the study, but were significantly lower at several time points with the highest-dose regimen (2 mg E2V + 5 mg MPA) than with the lower-dose options (1 mg E2V + 2.5 mg MPA and 1 mg E2V + 5 mg MPA; P < 0.05). Adverse events declined in frequency over time with all regimens but throughout the study were more numerous with the highest-dose regimen than with lower doses (P = 0.0002). Conclusions. Continuous combined HRT was effective for the relief of climacteric symptoms in early postmenopausal women and was well tolerated.
ACCESSION #
41233332

 

Related Articles

  • Menopausal hormone therapy and venous thromboembolism. Bińkowska, Małgorzata // Menopausal Review / Przeglad Menopauzalny;2014, Vol. 13 Issue 5, p267 

    Menopausal hormone therapy (MHT) is the most effective method of treating vasomotor symptoms and other climacteric symptoms related to estrogen deficiency in peri- and postmenopausal period. In addition to estrogen replacement, women with preserved uterus require the addition of progestagen in...

  • Frequently Asked Questions; What women want to know. Hudson, Tori // Townsend Letter for Doctors & Patients;Nov2003, Issue 244, p157 

    Presents a question and answer advisory related to women's health. Alternative treatment for hot flashes; Recommendation of estradiol for replacement of estrogen in hormone therapy; Intake of black cohosh.

  • Studies look at hormones and health risks.  // Clinical Advisor;Nov2013, Vol. 16 Issue 11, p26 

    The article reports on findings that do not support the use of estrogen therapy for preventing cardiovascular or other chronic disease as of November 2013. It references a study in the 2013 issue of the"Journal of the American Medical Association" (JAMA). It states that for post-menopausal women...

  • Practice observed. Gray, Sarah; Newton, Catherine E. // Journal of the British Menopause Society;2003, Vol. 9 Issue 4, p178 

    The article focuses on the results of a study called the Women's Health Initiative study. The study included patients that were chosen from a database of a 12,500 semi-rural practice of Cornwall in England. Premique refers to a preparation of continuous combined hormonal replacement therapy...

  • Effects of Contraception on Bone Mineral Density. Walling, Anne D. // American Family Physician;3/1/2005, Vol. 71 Issue 5, p1004 

    Discusses research being done on the effects of hormonal contraception on bone mineral density (BMD). Reference to a study by A. B. Berenson et al, published in a May 2004 issue of the "Obstetrics and Gynecology"; Decrease in BMD of women using medroxyprogesterone acetate contraception;...

  • Comparison of Regimens Containing Oral Micronized Progesterone or Medroxyprogesterone Acetate on Quality of Life in Postmenopausal Women: A Cross-Sectional Survey. Fitzpatrick, Lorraine A.; Pace, Cindy; Wiita, Brinda // Journal of Women's Health & Gender-Based Medicine;May2000, Vol. 9 Issue 4, p381 

    A cross-sectional survey was conducted to examine quality of life (QOL) related to physiological, somatic, and vasomotor effects of changing progestogen treatment from medroxyprogesterone acetate (MPA) to micronized progesterone in postmenopausal women. Eligible women (n = 176) were currently...

  • Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis. Jabbar, Suhair; Drury, John; Fordham, John N.; Datta, Harish K.; Francis, Roger M.; Tuck, Stephen P. // Journal of Clinical Pathology;Apr2011, Vol. 64 Issue 4, p354 

    Background Osteoprotegerin (OPG) and receptor activator of nuclear factor ? B ligand (RANKL) play a critical role in the regulation of bone turnover, but the relative importance of these two cytokines in the pathogenesis of postmenopausal osteoporosis is controversial. Aim To investigate the...

  • In a lather from hot flashes? New rub comes to the rescue. Belden, Heidi // Drug Topics;11/3/2003, Vol. 147 Issue 21, p24 

    Reports on the introduction of estradiol topical emulsion Estrasorb to prevent menopausal hot flashes in women in the U.S. Reduction of the vasomotor symptoms of menopause; Description of drug delivery; Citation of drug's contraindications.

  • HORMONE REPLACEMENT, BIO-IDENTICAL AND CONVENTIONAL - where are we in 2009? Enstein, Michael // Australian Advanced Aesthetics;Sep2009, Issue 3, p44 

    The article discusses the conventional hormone replacement therapy (HRT) which is being considered safe for women in their early post-menopausal period. It looks into the findings of the Women's Health Initiative Trial (WHI) on the recommendation of the HRT to treat women during their...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics